中国医疗体系报告,在创新产品的推动下,中国医疗体系收入和利润增长显著。 China Medical System reports significant revenue and profit growth, driven by innovative products.

中国医疗系统控股有限公司(CMS)在2025年上半年的收入增长了10.8%,净利润增长了3.1%。 China Medical System Holdings Limited (CMS) saw a 10.8% increase in revenue and a 3.1% rise in net profit for the first half of 2025. 来自非本国VBP独家/品牌产品和创新产品的收入同比增长20.6%,占总收入的62.1%。 Revenue from non-National VBP exclusive/branded products and innovative products grew 20.6% year-on-year, accounting for 62.1% of total revenue. 商品管理系统的战略重点是产品创新、商业模式改革和国际扩张,这种战略重点已转化为大幅度增长,预计新的药物和治疗方法将推动未来的业绩。 CMS's strategic focus on product innovation, commercial model reform, and international expansion has translated into significant growth, with new drugs and treatments expected to drive future performance.